Low-dose chemotherapy combined with NK cell-based immunotherapy as a treatment for triple negative breast cancer
Year: 2019
Type: dissertation
Abstract: Despite considerable progress and the emerging use of immunotherapies, chemotherapy remains the only routine clinical option for treating triple negative breast cancer (TNBC). However, this is associated with severe toxicity, is not effective in all patients and chemo-resistance can develop. NK cells are emerging as powerful tools for cancer immunotherapy and we hypothesised that NK cell-based therapies could be improved by combining them with other approaches that modify various components of the tumour and its environment and renders tumours more sensitive to NK cell cytotoxicity. \n \nIn addition to being less toxic and having a lower impact on a patient’s quality of life, evidence suggests that low-dose metronomic chemotherapy modulates adaptive and innate anti-tumour immune responses. Accordingly, the aim of this study was to enhance anti-tumour activity of adoptively transferred NK-cells using low-dose metronomic chemotherapy. \n \nHerein, the effect of treatment with low-dose doxorubicin on the phenotype of human breast cancer cell lines corresponding to different molecular subtypes of disease [MCF-7 (Luminal A); SK-BR-3 (Her2+); MDA-MB-468 (Triple Negative); MDA-MB-231/RFP/LUC (Triple Negative)] and their sensitivity to NK cell killing was investigated, as was the capacity of combining low-dose doxorubicin and adoptive NK cell transfer to control the growth and metastasis of human MDA-MB-231 xenografts in immunedeficient mice. \n \nWe demonstrate that low-dose doxorubicin treatment halts the proliferation of breast cancer cells and triggers expression of natural killer (NK) cell ligands, enhances sensitivity to NK cell-mediated cytotoxicity in vitro and modulates important cancer pathways associated with invasion and metastasis. In vivo, the combination of low-dose doxorubicin with adoptive transfer of IL-2 activated human NK cells, reduced the growth of MDA-MB-231 cell-derived tumours in a pre-clinical murine xenograft model. \n \nThese findings confirmed the capacity of low-dose chemotherapy to sensitise tumours to NK cell cytotoxicity and indicated the therapeutic potential of combining low-dose chemotherapy and NK cell therapy for the treatment of patients with TNBC, for whom current therapies are largely ineffective.
Author: Sarra Idri
Institution: Nottingham Trent University
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W3164352656
